Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Ltd. is set to enhance its North American presence by acquiring RLS, America’s only Joint Commission-accredited radiopharmacy network, which will broaden patient access to radiopharmaceuticals across the U.S. This strategic move aims to integrate the supply chain and increase production capabilities, leveraging RLS’s extensive network to support Telix’s growth and product distribution. The acquisition is anticipated to be financially beneficial for Telix, contributing to its operational cash flow and expanding its manufacturing footprint.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
